A Randomised, Open Labelled, Phase I, Safety, Toxicity, and Exploratory Immunogenicity Evaluation of Therapeutic Immunisation +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy.

Trial Profile

A Randomised, Open Labelled, Phase I, Safety, Toxicity, and Exploratory Immunogenicity Evaluation of Therapeutic Immunisation +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs HIV DNA vaccine (Primary) ; Aldesleukin; Interleukin-2; Sargramostim; Somatropin
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Mar 2013 Final results reporting immunogenicity presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 07 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top